Skip to main content
    Paid monthly and annual subscribers can read every Medi-Chi book online — including clinical references and the TCM Textbook · downloads sold separatelySee the libraryClinical Education Tool — This platform provides educational resources for TCM practitioners and students. It does not issue medical certificates, prescriptions, or clinical diagnoses.
    respiratory

    Allergic bronchopulmonary aspergillosis

    Also known as: ABPA, Allergic bronchopulmonary Aspergillus disease, Aspergillus-associated allergic bronchopulmonary disease

    Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity lung disease associated with Aspergillus sensitisation, predominantly manifesting in patients with underlying asthma or cystic fibrosis. It is characterised by recurrent airway obstruction, cough, pulmonary infiltrates, and bronchiectasis, requiring respiratory specialist assessment and long-term monitoring. While conventional therapy utilises corticosteroids, antifungals, and biological agents in selected patients, Chinese medicine may be considered solely as adjunctive, individually assessed symptom support. The supplied consensus describes integrated care, but lacks validated acupuncture protocols or specific effect estimates for ABPA. A bronchiectasis review provides indirect evidence, and a small retrospective omalizumab study cannot establish comparative effectiveness. These traditional patterns represent clinical reference frameworks, not diagnostic criteria or proven ABPA treatments.

    Plain-English one-pager you can print or hand to a patient. Free, no sign-in needed.

    All clinical details on this page are for practitioner premium subscribers only.
    Checking your practitioner access
    Verifying your Medi-Chi access…

    Lifestyle & Diet

    • •Minimise exposure to visible mould, damp environments, and compost dust; arrange safe remediation rather than disturbing extensive mould independently.
    • •Cessation of smoking and vaping is recommended; patients should avoid aerosolised irritants and maintain a smoke-free domestic environment.
    • •Maintain adherence to prescribed respiratory pharmacotherapy and specialist appointments; do not taper corticosteroid dosages without medical supervision.
    • •Calibrate physical exertion to remain within individual respiratory tolerance; maintain a clinical diary recording cough frequency, sputum characteristics, bronchodilator requirements, and nocturnal awakenings.

    Cautions & Contraindications

    See sources
    • •Do not substitute acupuncture or herbs for corticosteroids, antifungals, biologics or respiratory review. Defer elective adjunctive treatment during suspected acute deterioration. The consensus supports integrated management, not replacement care.[]
    • •Chest tightness with new dyspnoea must not be managed solely as qi stagnation or phlegm. Stop treatment and arrange urgent assessment when a cardiac cause is possible.[]
    • •Require full medicine reconciliation before prescribing herbs alongside corticosteroids or antifungals, including review of hepatic risk, potassium and blood pressure where relevant. The supplied consensus abstract does not establish formula-specific interaction safety.[]
    • •Do not infer that acupuncture is safe or effective for ABPA from a general bronchiectasis review. Obtain consent that the supplied abstracts provide no ABPA-specific controlled acupuncture outcomes or detailed procedural safety data.[,]

    When to reassess or seek care again

    See sources

    If medically stable, review adjunctive care after 2–4 weeks using cough severity on a 0–10 scale, nights disturbed per week, reliever use, sputum changes and activity tolerance. Record adverse effects at every visit. Stop or revise adjunctive treatment if there is no meaningful symptom benefit. Refer earlier for deterioration, increased reliever requirement, bleeding, fever or suspected adverse reactions. Specialist-directed lung function, imaging and laboratory monitoring remain separate; biomarker changes alone do not demonstrate adjunctive benefit.

    Explore more diseases

    Sources & Further Reading

    Clinical guidance, red flags and safety notes on this page draw on the following current sources alongside the classical references above.

    1. Zhonghua yi xue za zhi · 2026
    2. Frontiers in immunology · 2026
    3. Frontiers in cardiovascular medicine · 2026
    4. Chinese medicine · 2026

    Educational reference for licensed practitioners. Not a substitute for individual clinical assessment. Refer to conventional care for any red-flag or undiagnosed presentation.